Roche Nabs Emergency Use Authorization From FDA for Multiplex SARS-CoV-2, Flu Test

NEW YORK – Roche announced Friday that its Cobas SARS-CoV-2 & Influenza A/B test received Emergency Use Authorization from the US Food and Drug Administration. 

The RT-PCR test runs on Roche's Cobas 6800/8800 systems and is intended to qualitatively detect and differentiate SARS-CoV-2, influenza A, and influenza B from one nasal or nasopharyngeal sample. The multiplex test is also available in countries accepting the CE mark.